Logo image of CLOV

CLOVER HEALTH INVESTMENTS CO (CLOV) Stock Fundamental Analysis

NASDAQ:CLOV - Nasdaq - US18914F1030 - Common Stock - Currency: USD

2.145  -0.06 (-2.94%)

Fundamental Rating

2

Taking everything into account, CLOV scores 2 out of 10 in our fundamental rating. CLOV was compared to 103 industry peers in the Health Care Providers & Services industry. The financial health of CLOV is average, but there are quite some concerns on its profitability. CLOV is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CLOV had negative earnings in the past year.
CLOV had a negative operating cash flow in the past year.
In the past 5 years CLOV always reported negative net income.
CLOV had negative operating cash flow in 4 of the past 5 years.
CLOV Yearly Net Income VS EBIT VS OCF VS FCFCLOV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -200M -400M -600M

1.2 Ratios

With a Return On Assets value of -4.30%, CLOV is not doing good in the industry: 66.02% of the companies in the same industry are doing better.
CLOV's Return On Equity of -7.47% is in line compared to the rest of the industry. CLOV outperforms 42.72% of its industry peers.
Industry RankSector Rank
ROA -4.3%
ROE -7.47%
ROIC N/A
ROA(3y)-28.89%
ROA(5y)-29.85%
ROE(3y)-60.71%
ROE(5y)-58.55%
ROIC(3y)N/A
ROIC(5y)N/A
CLOV Yearly ROA, ROE, ROICCLOV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CLOV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLOV Yearly Profit, Operating, Gross MarginsCLOV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

More info and screens

5

2. Health

2.1 Basic Checks

CLOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CLOV has more shares outstanding
Compared to 5 years ago, CLOV has more shares outstanding
There is no outstanding debt for CLOV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CLOV Yearly Shares OutstandingCLOV Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M
CLOV Yearly Total Debt VS Total AssetsCLOV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

CLOV has an Altman-Z score of 0.09. This is a bad value and indicates that CLOV is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CLOV (0.09) is worse than 76.70% of its industry peers.
There is no outstanding debt for CLOV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.09
ROIC/WACCN/A
WACC8.86%
CLOV Yearly LT Debt VS Equity VS FCFCLOV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 1.54 indicates that CLOV should not have too much problems paying its short term obligations.
The Current ratio of CLOV (1.54) is comparable to the rest of the industry.
CLOV has a Quick Ratio of 1.54. This is a normal value and indicates that CLOV is financially healthy and should not expect problems in meeting its short term obligations.
CLOV has a Quick ratio of 1.54. This is comparable to the rest of the industry: CLOV outperforms 56.31% of its industry peers.
Industry RankSector Rank
Current Ratio 1.54
Quick Ratio 1.54
CLOV Yearly Current Assets VS Current LiabilitesCLOV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

CLOV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 88.46%, which is quite impressive.
The Revenue has grown by 8.77% in the past year. This is quite good.
CLOV shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.34% yearly.
EPS 1Y (TTM)88.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
Revenue 1Y (TTM)8.77%
Revenue growth 3Y-2.34%
Revenue growth 5YN/A
Sales Q2Q%34.07%

3.2 Future

Based on estimates for the next years, CLOV will show a very strong growth in Earnings Per Share. The EPS will grow by 41.27% on average per year.
Based on estimates for the next years, CLOV will show a quite strong growth in Revenue. The Revenue will grow by 14.96% on average per year.
EPS Next Y-41.67%
EPS Next 2Y-18.23%
EPS Next 3Y24.79%
EPS Next 5Y41.27%
Revenue Next Year22.74%
Revenue Next 2Y22.47%
Revenue Next 3Y17.36%
Revenue Next 5Y14.96%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CLOV Yearly Revenue VS EstimatesCLOV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1B 2B 3B 4B
CLOV Yearly EPS VS EstimatesCLOV Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -0.5 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CLOV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLOV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLOV Price Earnings VS Forward Price EarningsCLOV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40 -60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLOV Per share dataCLOV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as CLOV's earnings are expected to grow with 24.79% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-18.23%
EPS Next 3Y24.79%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CLOV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLOVER HEALTH INVESTMENTS CO

NASDAQ:CLOV (8/8/2025, 2:14:08 PM)

2.145

-0.06 (-2.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners26.15%
Inst Owner Change0.52%
Ins Owners3.36%
Ins Owner Change-4.44%
Market Cap1.09B
Analysts76.36
Price Target4.18 (94.87%)
Short Float %9.04%
Short Ratio3.96
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)69.83%
Min EPS beat(2)39.67%
Max EPS beat(2)100%
EPS beat(4)4
Avg EPS beat(4)77.7%
Min EPS beat(4)39.67%
Max EPS beat(4)120.14%
EPS beat(8)8
Avg EPS beat(8)54.43%
EPS beat(12)11
Avg EPS beat(12)42.86%
EPS beat(16)13
Avg EPS beat(16)8.81%
Revenue beat(2)0
Avg Revenue beat(2)-11.46%
Min Revenue beat(2)-13.64%
Max Revenue beat(2)-9.27%
Revenue beat(4)1
Avg Revenue beat(4)-6.52%
Min Revenue beat(4)-13.64%
Max Revenue beat(4)3.1%
Revenue beat(8)4
Avg Revenue beat(8)-2.24%
Revenue beat(12)8
Avg Revenue beat(12)0.42%
Revenue beat(16)12
Avg Revenue beat(16)7.25%
PT rev (1m)0%
PT rev (3m)-1.2%
EPS NQ rev (1m)0%
EPS NQ rev (3m)72.5%
EPS NY rev (1m)0%
EPS NY rev (3m)30.56%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.21%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.73
P/FCF N/A
P/OCF N/A
P/B 3.25
P/tB 3.28
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS2.92
BVpS0.66
TBVpS0.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.3%
ROE -7.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.89%
ROA(5y)-29.85%
ROE(3y)-60.71%
ROE(5y)-58.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover2.55
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 87.63%
Cap/Sales 0.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.54
Quick Ratio 1.54
Altman-Z 0.09
F-Score5
WACC8.86%
ROIC/WACCN/A
Cap/Depr(3y)171.94%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.1%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
EPS Next Y-41.67%
EPS Next 2Y-18.23%
EPS Next 3Y24.79%
EPS Next 5Y41.27%
Revenue 1Y (TTM)8.77%
Revenue growth 3Y-2.34%
Revenue growth 5YN/A
Sales Q2Q%34.07%
Revenue Next Year22.74%
Revenue Next 2Y22.47%
Revenue Next 3Y17.36%
Revenue Next 5Y14.96%
EBIT growth 1Y81.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year196.09%
EBIT Next 3Y61.57%
EBIT Next 5YN/A
FCF growth 1Y88.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y89.13%
OCF growth 3YN/A
OCF growth 5YN/A